Wellnex Life Limited

WNX · AIM · Retail · mcap £4.0m · 5.5p

Wellnex Life is an Australian consumer health company that owns and sells over-the-counter brands and makes products for others under contract. It sells mainly through Australian retailers and pharmacies and is expanding into the UK, New Zealand and other markets.

Recent signals

Negative 5 Oct 2026

Director Jeffrey Yeh sold 4.4m shares at A$0.08

Left holding 100,200 shares (0.1%); an insider sale. 5 Oct 2026

Mixed 11 Sep 2026

Sale of flagship Pain Away brand to repay all debt

Converts main brand into cash of A$19.8m and retires about A$10.2m borrowings, leaving a smaller business with licensing and contract manufacturing. 11 Sep 2026 6 Aug 2026

Positive 1 Sep 2026

Cost-cutting turnaround; positive operating cash flow in Q3 and Q4 FY26

Net loss fell 70.8% and H2 operating cash flow was +A$0.5m versus -A$3.1m in H1. 1 Sep 2026 31 Jul 2026

Negative 1 Sep 2026

Going concern uncertainty and repeated extensions of former directors' loans

Cash was A$862k at 30 June 2026 and director loans repayment was deferred several times. 1 Sep 2026 31 Jul 2026 23 Apr 2026

Negative 12 Mar 2026

Heavy board and CEO turnover; no permanent CEO

Both joint CEOs and several directors left in 2025; a permanent CEO appointment was described as advanced in March 2026. 12 Mar 2026 21 Oct 2025

Capital actions

2026-08-06 disposal · A$19.8m – Pain Away sold to Mentholatum, plus earn-out up to A$1.5m; completed 11 Sept 2026 6 Aug 2026
2026-04-23 debt refinancing · A$0.15m – Former directors' ~A$2.88m loans extended to 21 July 2026, A$150,000 fee, 10% interest 23 Apr 2026
2026-03-27 disposal · A$0.05m – Wakey Wakey and Nighty Night brands and inventory sold for cash 1 Sep 2026
2025-09-19 debt refinancing · A$2.5m – Additional Reach Wholesale facility, 24 months at 14% 19 Sep 2025
2025-07-31 debt refinancing · A$2.825m – Reach Wholesale loan facility, 24 months at 14%, secured over key subsidiaries 31 Jul 2025
2025-03-27 placing · £0.155m – WRAP Retail Offer, 488,216 new shares 27 Mar 2025
2025-03-21 placing · £5.22m – AIM admission placing at £0.3175 per share; proceeds used to eliminate over A$13m debt 21 Mar 2025

From the company's own announcements · not investment advice

Company filings. Not investment advice.